Naraev, Boris G <br/><br/>
Current status and perspectives of targeted therapy in well-differentiated neuroendocrine tumors.  [electronic resource] 

 -  Oncology  2012 
 - 117-27 p.  digital 
<br/><br/> Publication Type: Journal Article; Review 
<br/><br/><label>ISSN: </label>1423-0232 
<br/><br/><label>Standard No.: </label>10.1159/000339539  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antineoplastic Agents--therapeutic use<br/>Benzenesulfonates--therapeutic use<br/>Cell Differentiation<br/>ErbB Receptors--metabolism<br/>Everolimus<br/>Histone Deacetylases--metabolism<br/>Humans<br/>Immunologic Factors--therapeutic use<br/>Indazoles<br/>Indoles--pharmacology<br/>Molecular Targeted Therapy--methods<br/>Neuroendocrine Tumors--drug therapy<br/>Niacinamide--analogs & derivatives<br/>Pancreatic Neoplasms--drug therapy<br/>Phenylurea Compounds<br/>Pyridines--therapeutic use<br/>Pyrimidines--therapeutic use<br/>Pyrroles--pharmacology<br/>Receptors, Somatostatin--metabolism<br/>Sirolimus--analogs & derivatives<br/>Sorafenib<br/>Sulfonamides--therapeutic use<br/>Sunitinib<br/>TOR Serine-Threonine Kinases--antagonists & inhibitors<br/>Vascular Endothelial Growth Factor A--metabolism